Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.892 EUR | +27.49% | 0.00% | 0.00% |
Apr. 10 | Aegon: successful placement of bond issue | CF |
Apr. 10 | Aegon Prices $760 Million Note for General Corporate Purposes | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its low valuation, with P/E ratio at 8.42 and 6.7 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 10.89B | - | ||
+16.17% | 79.51B | B- | ||
+6.49% | 50.22B | B+ | ||
+1.35% | 48.11B | B | ||
+9.53% | 42.2B | B+ | ||
+6.55% | 39.71B | B+ | ||
+20.13% | 37.78B | B | ||
+2.84% | 30.07B | B | ||
-7.77% | 27.56B | B- | ||
-16.21% | 24.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AGN Stock
- 1AGN Stock
- Ratings Aegon Ltd.